Trial: 201910098

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Phase

II

Principal Investigator

Huang, Frederick

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov